Table 1 CSP#2014: VA-BRAVE eligibility criteria
Inclusion criteria | Exclusion criteria |
|---|---|
Use of opioids within 30 days prior to consent or within 30 days prior to entry into a supervised setting Meets DSM-5 criteria for moderate to severe OUD Referred to/seeking treatment for OUD New episode of care, defined as requiring induction on buprenorphine OR taking a form of prescribed medication treatment for OUD continuously for < 30 days prior to consent | Veterans < 18 years of age Females unwilling to practice an effective method of birth control for the duration of the study History of significant adverse effects from buprenorphine and/or naloxone Recent suicidal or homicidal ideation or psychosis that requires hospitalization Unable or unwilling to provide consent Meets criteria for current DSM-5 sedative hypnotic use disorder Pending felony charges Conditions which, in the judgement of the Local Site Investigator, make it unlikely the patient can participate in or complete the 52-week active phase of the study, including current moderate-to-severe COVID-19 symptoms with a risk of intubation or critical illness Is actively participating in another interventional clinical trial for which a waiver of dual-enrollment with VA-BRAVE has not been obtained |